Efficacy and Safety of Guihuang Formula in Treating Type Ⅲ Prostatitis Patients with Dampness-Heat and Blood Stasis Syndrome: A Randomized Controlled Trial  

作　　者：LIU Sheng-jing DENG Ying-jun ZENG Yin ZHAO Ming GUO Jun GAO Qing-he 

机构地区：[1]Department of Andrology,Xiyuan Hospital of China Academy of Chinese Medical Sciences,Beijing(100091),China [2]Graduate School of China Academy of Chinese Medical Sciences,Beijing(100700),China [3]Department of Andrology,Beijing Chinese Medicine Hospital Affiliated to Capital Medical University,Beijing(100010),China [4]Graduate School,Beijing University of Chinese Medicine,Beijing(100029),China

出　　处：《Chinese Journal of Integrative Medicine》2022年第10期879-884,共6页中国结合医学杂志（英文版）

基　　金：Supported by the National Natural Science Foundation of China (No.82104880);Scientific and Technological Innovation Project of China Academy of Chinese Medical Sciences (No.CI2021A02208);the Nursery Project of Xiyuan Hospital of China Academy of Chinese Medical Sciences (No.2019XYMP-23)。

摘　　要：Objective: To observe the efficacy and safety of Guihuang Formula(GHF) in treating patients with type Ⅲ prostatitis and Chinese medicine syndrome of dampness-heat and blood stasis. Methods: Sixty-six type Ⅲ prostatitis patients with dampness-heat and blood stasis syndrome were randomly divided into the treatment group(GHF) and the control group(tamsulosin) using a random number table, with 33 cases each group. The treatment group received GHF twice a day, and the control group received tamsulosin 0.2 mg once daily before bedtime. Patients in both groups received treatment for 6 weeks and was followed up for 2 weeks. The outcomes included the National Institute of Health Chronic Prostatitis Symptom Index(NIH-CPSI) score, Chinese Medicine Symptoms Score(CMSS), expressed prostatic secretions(EPS) and adverse events(AEs). Results: After treatment, the NIH-CPSI total score and domain scores of pain discomfort, urination and quality of life decreased significantly from the baseline in both groups(P<0.05). The CMSS score decreased in both groups(P<0.05). The white blood cell(WBC) count decreased and lecithin body count increased in both groups(P<0.05). GHF showed a more obvious advantage in reducing the pain discomfort and quality of life domain scores of NIH-CPSI, reducing the CMSS score, increasing the improvement rate of the WBC and lecithin body counts, compared with the control group(P<0.05). There were no significant differences in decreasing urination domain score of NIH-CPSI between two groups(P>0.05). In addition, no serious AEs were observed. Conclusion: GHF is effective in treating type Ⅲ prostatitis patients with dampness-heat and blood stasis syndrome without serious AEs.(Registration No. ChiCTR1900026966)

关 键 词：typeⅢprostatitis dampness-heat and blood stasis syndrome Guihuang Formula Chinese medicine randomized controlled trial 

分 类 号：R277.5[医药卫生—中医学]